OCRBird_Proposal_Spring-2016.pdf (259 kB)
Project Proposal

Completion Date



Todd Hagobian


Eleven healthy adults (3 M, 8 F; 21.3 ± 0.8 yr; 24.0 ± 3.8 kg/m2) were block randomized to a single ingestion of placebo, low dose BPA (4 μg/kg-bw), or high dose BPA (50 μg/kg-bw) on separate days in a double-blinded, crossover fashion. Blood was drawn at baseline and repeatedly for 3 hours following each condition. Data collection has been completed for 11 subjects, and analyses of plasma BPA concentrations in these subjects have shown three distinct concentrations for high, low, and placebo conditions. Preliminary analyses of plasma insulin concentrations in 3 subjects appear to show differences in concentrations between conditions. In order to analyze insulin, proinsulin, estrogen, and glucose concentrations, this study will be continued into Summer 2017. Based on preliminary findings, we anticipate that oral ingestion of BPA will negatively affect risk markers in the pathogenesis of Type 2 Diabetes.


Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.